Search Results: (30 results)

In this study, researchers are testing the safety and effectiveness of the immunotherapy dostarlimab (Jemperli) as a non-surgery alternative  treatment option for patients with early-stage dMMR or MSI-H endometrial cancer and a strong desire for fertility preservation. Doctors will evaluate patients' response to dostarlimab; patients whose tumors respond completely can be followed with close surveillance and no surgery. 

The researchers are doing this study to see if the drug romosozumab is effective at helping with bone formation in people with metastatic breast cancer (MBC) that has spread to the bones. The researchers will also look at bone breakdown (resorption) in participants and determine if romosozumab is a safe treatment for osteoporosis in people with MBC that has spread to the bones.

This study tests whether COM701 (an anti‑PVRIG immunotherapy) given every 3 weeks as maintenance can delay cancer growth after a good response to platinum chemotherapy. Adults with relapsed platinum‑sensitive ovarian, fallopian tube, or primary peritoneal cancer are randomized 2:1 to COM701 or placebo.

This study is testing a new targeted drug called daraxonrasib to see if it helps people with metastatic pancreatic cancer live longer or keep their cancer from growing longer than standard chemotherapy alone. Researchers are comparing daraxonrasib by itself or combined with chemotherapy to standard chemotherapy.

This study is evaluating the addition of ART6043, a novel targeted therapy, to olaparib, a standard treatment, in adults with HER2-negative advanced or metastatic breast cancer and an inherited germline BRCA mutation.

People with Lynch syndrome currently rely on regular colonoscopies to screen for colorectal cancer. Researchers are studying whether a simple stool-based test called the fecal immunochemical test (FIT) can help identify people who may need a colonoscopy while reducing the burden of frequent screening. This study will compare FIT results with colonoscopy findings in people with Lynch syndrome.

This study is for adults with advanced/metastatic HR-positive, HER2-negative advanced or metastatic breast cancer who have previously been treated with a CDK4/6 inhibitor and have received two or less treatments for their advanced metastatic breast cancer.

Phase 2 study comparing talazoparib with or without Enzalutamide in patients with metastatic castration-resistant prostate cancer and an HRR mutation after progression on Abiraterone Acetate or Darolutamide

This trial will study the safety, tolerability, and initial effectiveness of MOMA-341, a new type of targeted therapy, alone or in combination with a standard chemotherapy (irinotecan) or together with an immunotherapy to treat people with advanced or metastatic cancers with certain types of mutations.

This study is testing a new drug called DT2216 in combination with the chemotherapy drug paclitaxel for people whose ovarian cancer has returned and no longer responds to platinum-based chemotherapy.

This clinical trial is testing whether using acupressure guided by the EnergyPoints App can reduce cancer-related fatigue and improve sleep in adult cancer survivors residing in the U.S.

We are conducting a fully-online research study to learn more about how genes affect your risk of breast cancer. No office visit is required. Participants provide consent online, answer questions online about their health and medical history, and provide DNA via a saliva sample using a pre-paid mailer through the mail. In return for participation, study participants may receive information about their genetic ancestry for free.

Today, researchers are learning about breast cancer from a small subset of patients, who are not representative of all breast cancer patients. ShareForCures® is an online registry that offers people who have been diagnosed with breast cancer a way to participate in research by connecting information about themselves with their breast cancer diagnosis, medical records, genomics. Participation is open to anyone adult, living in the United States, and who has been diagnosed with breast cancer.

The purpose of this study is to understand gastric (stomach) cancer risk among people with an inherited (germline) mutation in genes that are linked to an increased risk of certain cancers, including APC, ATM, BRCA1, BRCA2, CDH1, CHEK2, PALB2, Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM), MUTYH, STK11, and other genes linked to increased cancer risk. 

A diagnosis of cancer or other serious medical condition changes everything — including your mental health. Those experiencing negative mental health changes after receiving a diagnosis may be dealing with what is known as Adjustment Disorder.

Study enrolling breast cancer survivors, caregivers, and individuals at high risk for breast cancer. Participants may complete surveys or participate in an interview, depending on availability

The Vanguard Study is looking at how multi-cancer detection (MCD) blood tests could fit into cancer screening.

Researchers are studying certain rare variants in the BRCA1 and BRCA2 genes that may affect cancer risk differently than more common harmful variants in BRCA1 and BRCA2. The goal is to learn more about the cancer risks associated with these specific variants and help improve recommendations for cancer screening and prevention.

This Patient and Caregiver survey was created by volunteers from two non-profit groups to learn more about immunotherapy side effects. No personal information is collected. Goals include sharing results with doctors, care teams, and patient groups; gathering information about better ways to handle immune-related side effects; and working with researchers to find and test better ways to treat immune-related side effects.

This study is collecting feedback on educational materials about breast MRI from Black and Latina women ages 18-74 who are at high risk for breast cancer.

This study is for people with prostate cancer that is considered high risk for recurrence. It compares two radiation therapy schedules to see whether a shorter course of treatment works as well as the standard, longer course at preventing the cancer from coming back or spreading.

Diverse volunteers are invited to participate in this research study about the patient experience in genetic counseling.

This early-phase study is looking at the safety, side effects, and best dose of the medication pidnarulex for treating advanced or metastatic cancers. Pidnarulex blocks a certain protein called Pol 1 that cells need to repair DNA damage. 

This is a Phase III, randomized, global, open-label clinical trial to see if a new drug Daraxorasib (RMC-6236) helps prevent pancreatic cancer from returning after surgery and chemotherapy.

Researchers are studying whether the targeted therapy ETX-19477 is a safe and effective treatment option for people with metastatic or advanced solid tumors. ETX-19477 is a type of drug known as a PARG inhibitor. It works by interfering with cancer cells' ability to repair damage to their DNA. Researchers hope this may slow tumor growth or cause cancer cells to die.The goal of this study is to find the safest and most effective dose of ETX-19477 for treating metastatic or advanced cancers. The study is currently enrolling people with a BRCA1 or BRCA2 mutation. 

This observational study follows participants over time to better understand the long-term effects of nipple-sparing mastectomy.

This study will explore how “dear family letters” influence understanding of genetic risk and cascade testing among individuals and families affected by hereditary cancer.

Researchers are studying whether a smartphone app can help improve quality of life for Black men with prostate cancer. The app is designed specifically for Black men and includes:

• Information about prostate cancer.
• A way to track symptoms and share concerns with healthcare providers.
• Personal stories from other people with similar experiences.

This study is testing whether taking daraxonrasib, a new oral cancer medicine, after surgery and standard chemotherapy can help people with pancreatic cancer stay cancer-free for longer.

We are conducting a clinical trial to see if our education materials help people at risk for Lynch syndrome decide about seeking genetic services, such as genetic counseling and testing.